Irhythm Holdings, Inc. · NASDAQ:IRTC
Irhythm — Q1 2023 Earnings Presentation
11 slides from Irhythm's earnings presentation, May 4, 2023
Slide 1: iRhythm Technologies First Quarter 2023 Results
iRhythm Technologies First Quarter 2023 Results May 4, 2023
Slide 2: Safe harbor statement
Safe harbor statement Certain data in this presentation was obtained from various external sources, and neither “iRhythm” or the You should not rely upon forward-looking statements as predictions of future events. Although we believe that “Company” nor its affiliates or representatives has verified
Slide 3: iRhythm at a glance: patients served, revenue CAGR, data
6+ Million >30% Patients served Five-year revenue CAGR ~25% ~1.5 Million Penetration in core Patients served U.S. ambulatory cardiac annually and growing monitoring market a 35+ 66 Peer-reviewed Countries and states where we publications have employees 1.5 Billion Hours of curated ~1,800 ECG data Gl
Slide 4: CAMELOT: The Cardiac Ambulatory Monitor EvaLuation of Outcomes and Times to events
CAMELOT: The Cardiac Ambulatory Monitor EvaLuation of Outcomes and Times to events The real-world evidence in the CAMELOT study associates Zio XT with these positive outcomes 1. Reynolds et al. Comparative effectiveness of ambulatory monitors for arrhythmia diagnosis: A retrospective analysis of Med
Slide 5: Differentiated platform technology with catalyst-rich pipeline
Differentiated platform technology with catalyst-rich pipeline 2023 2024 Zio Monitor Limited Market Release Zio Monitor US Commercial Launch Zio Monitor Launch into International Markets Zio MCT US Commercial Launch Zio Watch Market Evaluation: IRB Use & Clinical Studies Commercial Pilots Commercial
Slide 6: First quarter 2023 financial performance
First quarter 2023 financial performance GLOBAL NET REVENUE GROSS PROFIT MARGIN (USD, MILLIONS) $112.6 $111.4 69.9% $102.1 $103.9 $92.4 68.8% 68.3% 67.9% 66.9% 1Q2022 2Q2022 3Q2022 4Q2022 1Q2023 1Q2022 2Q2022 3Q2022 4Q2022 1Q2023 ADJUSTED OPERATING EXPENSES ADJUSTED EBITDA MARGIN (USD, MILLIONS) R&D
Slide 7: 2023 annual revenue and profitability guidance
2023 annual revenue and profitability guidance NET REVENUE GROSS MARGIN ADJUSTED OPERATING ADJUSTED EBITDA (USD, MILLIONS) EXPENSES (USD, MILLIONS) MARGIN $480 - 69 - 70% $417 - (0.5)%- $490 of $427 0.5% of million revenues million revenues Adjusted operating expenses exclude impact from non-GAAP bu
Slide 8: Addressing the future focus of healthcare
Addressing Expanding the future focus existing markets of healthcare while extending into adjacent markets Out-paced Delivering revenue growth meaningful from massive improvements in underpenetrated financial profile markets on a global scale
Slide 9: Appendix
Appendix GAAP Reconciliations
Slide 10: Reconciliation of net loss to adjusted EBITDA
Reconciliation of net loss to adjusted EBITDA Adjusted EBITDA is a non-GAAP measurement of net loss or income excluding interest, taxes, depreciation and amortization, stock-based compensation expense, impairment and restructuring charges, and transformation costs. We believe that adjusted EBITDA is
Slide 11: Reconciliation of GAAP to Non-GAAP financial information
Reconciliation of GAAP to Non-GAAP financial information THREE MONTHS ENDED MARCH 31, ADJUSTED NET LOSS RECONCILIATION 2023 2022 Net loss, as reported $ (39,109) $ (50,609) Impairment and restructuring charges — 26,608 Transformation costs 5,686 258 Adjusted net loss $ (33,423) $ (23,743) THREE MONT